Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Subscribe now to continue reading.

In an interview with BioPharmaDispatch yesterday, Medicines Australia chief executive Liz de Somer made the following point, "It is a time for sensitivity and our industry needs to communicate with each other and externally mindful of the extent of this crisis and how it is very seriously impacting millions of people." …

Subscribe now to continue reading.

Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Latest Video

Most Read

Is the institution able to change in response to something it may not be capable of recognising?

Lower than expected uptake of new therapies impacts PBS spend

Mark Butler announces PBS listings for 1 October

Another blow for Australians with severe dermatitis as PBS falters again

The symptoms have been identified, but the widely held belief about the cause is a miss

New Stories

The symptoms have been identified, but the widely held belief about the cause is a miss

UK companies are granted more time to decide on pricing agreement

Anatara strengthens board with the appointment of Dirk van Dissel

CLINUVEL advances next-generation peptide drug formulations

Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy

Lower than expected uptake of new therapies impacts PBS spend

Chimeric reports encouraging early data from CHM CDH17 trial

Sign In

Sensitivity and understanding at the most difficult of times

This is a preview of subscriber content

Latest Video

Most Read

Is the institution able to change in response to something it may not be capable of recognising?

Lower than expected uptake of new therapies impacts PBS spend

Mark Butler announces PBS listings for 1 October

Another blow for Australians with severe dermatitis as PBS falters again

The symptoms have been identified, but the widely held belief about the cause is a miss

Follow Us

New Stories

The symptoms have been identified, but the widely held belief about the cause is a miss

UK companies are granted more time to decide on pricing agreement

Anatara strengthens board with the appointment of Dirk van Dissel

CLINUVEL advances next-generation peptide drug formulations

Alterity Therapeutics targets major market with ATH434 in Multiple System Atrophy

Lower than expected uptake of new therapies impacts PBS spend

Chimeric reports encouraging early data from CHM CDH17 trial